Streetbeat News

Analyst Ratings

ORCL

Deutsche Bank analyst Brad Zelnick maintains a Buy rating on Oracle (NYSE:ORCL) and raises the price target from $120 to $135.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:02 pm

ADI

11 analysts have provided their ratings for Analog Devices (NASDAQ:ADI) in the last quarter, with 2 bullish, 7 somewhat bullish, and 2 indifferent. The average 12-month price target is $205.27, a 6.95% decrease from the previous average of $220.60.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:01 pm

LITE

In the last quarter, Lumentum Holdings (NASDAQ:LITE) received 3 bullish, 6 somewhat bullish, and 8 indifferent analyst ratings. The company's average 12-month price target is $54.47, down 18.6% from the previous average of $66.92.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:01 pm

ORCL

Barclays analyst Raimo Lenschow maintains an Equal-Weight rating on Oracle (NYSE:ORCL) and raises the price target from $113 to $126.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 4:01 pm

FWBI

In the last 3 months, 4 analysts have offered 12-month price targets for First Wave BioPharma (NASDAQ:FWBI), with an average price target of $12.0, a 25.0% decrease from the previous average price target of $16.00.

Portfolio Pulse from Benzinga Insights

June 13, 2023 | 4:00 pm

ORCL

Jefferies analyst Brent Thill maintains a Buy rating on Oracle (NYSE:ORCL) and raises the price target from $125 to $135.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 3:59 pm

CPA

HSBC analyst Alexandre Falcao maintains a Buy rating on Copa Holdings (NYSE:CPA) and lowers the price target from $143 to $138.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 3:58 pm

SYF

B of A Securities analyst Mihir Bhatia maintains a Neutral rating on Synchrony Financial (NYSE:SYF) and raises the price target from $37 to $38.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 3:58 pm

JBL

B of A Securities analyst Ruplu Bhattacharya maintains a Buy rating on Jabil (NYSE:JBL) and raises the price target from $91 to $108.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 3:57 pm

LEGN

BTIG analyst Justin Zelin maintains a Buy rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $85 to $90.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2023 | 3:56 pm